Stimulation of anti-tumor immunity via immune checkpoint inhibitors (ICI) such as anti-PD-1/PD-L1 and anti-CTLA-4 has proven successful for several tumor types, but results in breast cancer are still modest. Here, CTLA4 is linked to neoplasm.